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Abstract: Stenotrophomonas maltophilia has been recognized as an emerging nosocomial pathogen in
invasive infections of immunocompromised, severely debilitated patients with significant underlying
illnesses. The first-choice drug in these infections is sulfamethoxazole-trimethoprim (SMX/TMP), and
resistance to this antimicrobial is a daunting challenge for clinicians. The aim of this study was to
assess the prevalence of S. maltophilia bacteremia and SMX/TMP-resistance levels at a tertiary-care
university hospital. A total of 175 episodes of S. maltophilia bacteremia were identified (2008–2012:
n = 82, 2013–2017: n = 93; p = 0.061), 52% of affected patients were 60 years of age, and had recent
surgery, severe injuries or underlying conditions (malignant hematologic diseases and solid tumors) in
their history. Sixteen percent of isolates were resistant to SMX/TMP (2008–2012: n = 13.8%, 2013–2017:
n = 17.2%; p = 0.076), and out of the resistant strains, 32.7% were also resistant to levofloxacin and
colistin. Our findings on the SMX/TMP-resistance were similar to global literature data.
Keywords: Stenotrophomonas maltophilia; bacteremia; bloodstream infection; SMX/TMP;
sumetrolim-resistance; retrospective; literature review
1. Introduction
Stenotrophomonas maltophilia is a non-fermenting, oxidase-negative and catalase-positive aerobic
Gram-negative bacillus [1,2]. S. maltophilia is the only human opportunistic pathogen of the
Stenotrophomonas genus [2,3]. These bacteria are ubiquitous in the environment (frequently occurring
in the soil and natural waters), and due to their positively charged cell wall surface and fimbriae, they
can easily attach to and survive on various abiotic surfaces (e.g., irrigation fluids and tap water in
the healthcare setting) [3–6]. S. maltophilia is also a biofilm-producer, which has a protective effect
against drying-induced damage and hinders the functions of immune cells, inhibits the diffusion of
antimicrobial drugs in vivo and allows for persistence in central venous catheters (CVCs) [3–7].
Before the 1970s, S. maltophilia was considered an unusual, opportunistic pathogen with a
low rate of isolation and limited invasiveness because the pathogen must bypass the natural host
defenses to cause infection [1,2,8,9]. However, owing to the advancements in medical interventions
and pharmacological therapies (complex surgeries, cancer chemotherapy, immunosuppression for
organ transplantation), in addition to the developments in more sensitive and precise identification
methods in clinical microbiology, there have been more reports on S. maltophilia infections. Therefore,
this pathogen has been recognized as an emerging nosocomial pathogen in invasive infections of
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immunocompromised, severely debilitated patients with significant underlying illnesses [7,10,11].
There are more and more reports of isolated S. maltophilia outbreaks in intensive care units (ICUs) and
cancer wards [12,13]. The reported incidence of S. maltophilia nosocomial infections ranges between
7.1–37.7 cases/10,000 discharges, nevertheless, the incidence of these infections is directly proportionate
to the number of patients at risk. Furthermore, since the 2000s, the relevance of this pathogen in
community-acquired infections has also increased [14,15]. The most common manifestations of S.
maltophilia infections are tracheobronchitis and bacteremia, however, their pathogenic role has also been
described in meningitis, peritonitis [8,16–18], mastoiditis, ocular infections, infected wounds, skin and
soft tissue infections, invasive bone and joint infections and infections of the genitourinary tract [8,9,19].
Many S. maltophilia infections are polymicrobial. The co-pathogens in these infections are usually
other non-fermenting Gram-negative bacteria (Pseudomonas aeruginosa, Acinetobacter spp., Burkholderia
cepacia complex) or Staphylococcus aureus [1,2,8,9]. S. maltophilia pulmonary infections are usually
hospital-acquired and ventilator-associated (VAP). In patients with tumors of the hematopoietic and
lymphoid tissues and severe immunosuppression (e.g., HIV-infection), a fulminant-course syndrome
called fatal hemorrhagic pneumonia may occur [20,21]. S. maltophilia is also a well-known pathogen
in cystic fibrosis patients; the infection rate correlates well with disease progression and loss of lung
function, both in children and adults [22–24].
In S. maltophilia bacteremia, the source of the bacteria are usually the colonized/infected lungs,
a CVC-infection or the gastrointestinal tract [25]. Risk factors include prolonged hospitalization,
mechanical ventilation, admission to the intensive care unit (ICU), severe neutropenia and/or mucositis,
various underlying diseases (hematological malignancy), cytotoxic chemotherapy or radiotherapy,
corticosteroid therapy, recent surgical intervention or trauma, treatment with broad-spectrum antibiotics
(most notably carbapenems), total parenteral nutrition (TPN), and previously identified S. maltophilia
colonization [8,18,26,27]. S. maltophilia is a significant factor in morbidity and mortality, with the
associated mortality of bacteremia thought to be around 20–70% [19,28]. The risk of relapse after
therapy of catheter-associated bacteremia is very high, therefore the removal of the catheter and
surgical debridement is also recommended in addition to anti-infective therapy [8,18,26,27].
From a clinical perspective, the management of S. maltophilia infections may be quite
difficult [26]. This microorganism is intrinsically resistant to several classes of antibiotics, most notably
aminoglycosides (LPS changes and an acetyl-transferase enzyme) and most of the β-lactam antibiotics
(specifically carbapenems, owing to the production of a penicillinase (L1) and a cephalosporinase (L2)
enzyme), due to various resistance mechanisms (e.g., eﬄux pumps) [1,29,30]. Thus, broad-spectrum
antibiotic therapy may select for S. maltophilia in an in vivo environment, over other susceptible
pathogens [8,18,26,27]. The therapy of choice in these infections is sulfamethoxazole/trimetoprim
(co-trimoxazole; SMX/TMP), administered in 3–4 divided doses of 15 mg/kg/day [31–33]. Resistance to
SMX/TMP is mediated by modifications in the target genes sul1 and sul2 [34,35]. Resistance rates in
the Western Hemisphere range between 2–10%, however, some outliers with higher resistance levels
in Europe (Spain: 27%), and in other parts of the globe (Turkey: 10–15%, Taiwan: up to 25%, China
30–48%) have been reported [29,34,35]. In patients with malignant neoplasms, ICU patients and cystic
fibrosis (CF) patients, resistance levels may be even higher (20–80%) [10]. Resistance, hypersensitivity or
expected severe side effects related to SMX/TMP present a serious challenge to clinicians, as the evidence
supporting several antimicrobial drugs in S. maltophilia infections is not yet clear [36]. Nonetheless, a
recent meta-analysis has found that fluoroquinolones (a popular alternative to SMX/TMP) are equally
effective in the therapy of these infections [37]. For this reason, S. maltophilia has been listed by the
World Health Organization as one of the most concerning multidrug-resistant (MDR), nosocomial
pathogens worldwide [38–40]. Other drugs that may be considered (if S. maltophilia has shown
in vitro susceptibility) are tetracyclines (doxycycline, minocycline and tigecycline), fluoroquinolones
(ciprofloxacin, levofloxacin and moxifloxacin), ticarcillin/clavulanate, ceftazidime, colistin and some
other antibiotics such as moxalactam, rifampin and chloramphenicol [17,41]. In the empiric therapy of
S. maltophilia infections (especially in immunocompromised patients), SMX/TMP is usually combined
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with levofloxacin or ticarcillin/clavulanate, until susceptibility results are available, or if coverage of
additional pathogens is necessary [17,41].
The epidemiology of S. maltophilia infections varies greatly by the profile of the healthcare
institution and the geographic region. Therefore, the assessment of local data is essential to evaluate
trends over time and to reflect on the national situation compared to international data. The aim of this
study was to assess and describe the prevalence of bacteremia caused by S. maltophilia at a tertiary-care
hospital in Hungary retrospectively, during a 10-year study period (2008–2017), to assess the resistance
trends associated with this pathogen and to compare our findings with results of other studies in
Hungary and from the international literature.
2. Materials and Methods
2.1. Study Design
This retrospective cohort study was carried out using microbiological data collected from between
January 2008 to December 2017 at the Albert Szent-Györgyi Clinical Center (ASCC), an academic
primary- and tertiary-care teaching hospital in Szeged, Hungary. ASCC has a bed capacity of 1820-beds
(1465 active and 355 chronic beds) and annually serves more than 400,000 patients in the Southern
Great Plain of Hungary [42]. An electronic search (January 2008 till December 2017) of the MedBakter
laboratory information system (LIS) records were conducted by two authors (M.G. and E.U.). Isolates
were considered separate if they occurred more than 14 days apart or S. maltophilia isolates with
different antibiotic susceptibilities were detected. Time-to-positivity (TTP) data corresponding to the
positive blood culture bottles was also collected. Polymicrobial bacteremia was defined by the isolation
of more than one organism in a single blood culture. In addition, patient data was also collected on
patients who had at least one positive aerobic blood culture for S. maltophilia, which was limited to
demographic characteristics (age, sex) and the indication for blood culture sample submission.
2.2. Sample Processing, Identification and Antimicrobial Susceptibility Testing (AST)
The processing of blood culture bottles arriving to the Institute of Clinical Microbiology was
carried out according to guidelines in routine clinical bacteriology. Between 2008–2012, the BD Bactec
(Beckton Dickinson, Franklin Lakes, NJ, USA) detection system was employed in our Institute, while
from 2013 onwards, the BacT/ALERT 3D (bioMérieux, Marcy-l’Étoile, France) detection system was
used. Blood culture bottles were incubated for 5 days (21 days, if endocarditis was suspected) in the
abovementioned detection systems.
Between 2008–2012, presumptive phenotypic/biochemical methods and VITEK 2 ID (bioMérieux,
Marcy-l’Étoile, France) were used for bacterial identification, while after 2013, this was complemented
by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS;
Bruker Daltonik Gmbh. Gr.). The methodology of sample preparation for MALDI-TOF MS
measurements is described elsewhere [43]. Antimicrobial susceptibility testing (AST) for SMX/TMP
was performed using the disk diffusion method, the interpretation of the results was based on EUCAST
breakpoints (http://www.eucast.org; zone diameter > 16 mm, MIC < 4 mg/L) (Liofilchem, Abruzzo,
Italy). Susceptibility-testing for other antibiotics was performed in the case of SMX/TMP resistance:
non-species specific (NSS) breakpoints were applied in the case of tigecycline (TGC; S ≤ 0.25 mg/L, R >
0.5 mg/L) and levofloxacin (LEV; S ≤ 1 mg/L, R > 2 mg/L) using the E-test (Liofilchem, Abruzzo, Italy).
In the case of colistin (COL; S ≤ 4 mg/L, R > 4 mg/L), a Pseudomonas aeruginosa-specific breakpoint
was used and testing was performed using broth microdilution in cation-adjusted Mueller-Hinton
broth [34,44]. S. aureus ATCC 29213, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922 and
P. aeruginosa ATCC 27853 were used as quality control strains.
In the case of a SMX/TMP-resistant isolate, the in vitro susceptibility testing of additional
agents (see Section 1) is recommended. In addition, other antimicrobials need to be considered in
patients where SMX/TMP may not be used (e.g., sulfur allergy, severe renal impairment or where
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dosing may not be reliable). EUCAST currently only provides validated disk diffusion breakpoints
for SMX/TMP (in addition to the NSS breakpoints; http://www.eucast.org), while the Clinical and
Laboratory Standards Institute (CLSI) offers dilution testing breakpoints for SMX/TMP, ceftazidime,
chloramphenicol, levofloxacin, minocycline and ticarcillin/clavulanate, in addition to disk diffusion
testing breakpoints for SMX/TMP, levofloxacin and minocycline [45]. However, for some drugs, there
is insufficient evidence to establish breakpoints, therefore the clinical microbiologist cannot interpret
susceptibility results in the susceptible/resistant duality.
2.3. Statistical Analysis
Descriptive statistical analysis (including means or medians with ranges and percentages to
characterize data) was performed using Microsoft Excel 2013 (Redmond, WA, Microsoft Corp.).
Additional statistical analyses were performed with SPSS software version 24 (IBM SPSS Statistics
for Windows 24.0, IBM Corp. Armonk, NY, USA), using the χ2-test and two-sample-test (isolation
frequency and resistance trends). p values < 0.05 were considered statistically significant.
3. Results
A total of 175 episodes of S. maltophilia bacteremia were identified (17.5 ± 11.36/year, range:
8–33 isolates; highest in 2013, lowest in 2009) during the study period. The number of isolates between
2008–2012 was n = 82, while for 2013–2017, this number was n = 93. A considerable, but not significant
increase (p = 0.061; two-sample t-test) was observed in the isolation frequency in the second part of
the study period (2013–2017). The affected patients presented with a slight male dominance (57.71%);
the age distribution of patients was the following: 8.6% 0–5 years, 8.7% 6–17 years, 5.9% 18–35 years,
24.8% 36–59 years and 52.0% of patients were 60 years of age or older.
Indications for blood culture sample submission, associated with S. maltophilia bacteremia included
hematological malignancies (predominantly acute myeloid leukemia and multiple myeloma) and
solid tumors (lung, stomach and colon cancer) (21.1%), cardiovascular illnesses (17.7%), recent trauma
(including polytrauma and fractures of the skull and spine) (14.9%), burns (5.1%) or other reasons
(9.0%). Septicemia or other infectious processes, including meningitis, pleuritis or pneumonia were
reported in 16.5% and 15.7% of cases, respectively. The origin of positive blood culture isolates from
the ASCC corresponds to the abovementioned indications. The largest amount originated from the
various wards of the Department of Internal Medicine (39.1%), Intensive Care Units of different profiles
(cardiology–hematology, surgery and traumatology) (33.7%), the Department of Surgery (13.0%), the
Department of Pediatrics (9.8%) and the Department of Neurology (4.4%).
In 78.4% of relevant blood culture samples, S. maltophilia was the only isolated pathogen,
whereas in 21.6%, more than one (in 14.2% two and in 3.7% of both three and four) different
species could be isolated (Table 1). Gram-negative rods (species of Enterobacteriaceae and other
non-fermenting Gram-negative bacteria in equal measure; 44.0%) and Gram-positive cocci (44.0%)
were the most frequent species co-isolated. P. aeruginosa (in 10 cases) was the most frequent co-isolate.
Coagulase-negative staphylococci (CoNS) were also prevalent (in 17 cases), however, these strains are
presumably just skin contaminants, associated with inadequate care during the sampling procedure
for the blood culture bottles.
The average time-to-positivity (TTP) for the blood culture samples was 24.26 ± 19.98 h (range:
3.84–189 h). No significant association was observed during the change in blood culture incubation
systems (23.1 vs. 24.52 h; p < 0.05); however, there were relevant differences between the TTPs of
monobacterial and polymicrobial isolates (29.43 vs. 22.38 h; p = 0.032).
Eighty-four percent (range: 72–98%) of S. maltophilia blood culture isolates were susceptible
to SMX/TMP during the 10-year study period. This left 16.0% of isolates (2008–2012: 13.8%,
2013–2017: 17.2%; p = 0.076; two-sample t-test) resistant to the first-line drug, SMX/TMP. Out
of the SMX-TMP-resistant S. maltophilia strains that were tested with other antimicrobial drugs, 58.2%
of isolates (9.4% overall) were also resistant to tigecycline. Additionally, 32.7% of isolates (5.2% overall)
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were also resistant to levofloxacin and colistin, based on non-species-specific (NSS) breakpoints and
the colistin-breakpoint of P. aeruginosa, respectively.
Table 1. Bacteria co-isolated with S. maltophilia in bacteremia, 2008–2017.
Co-Isolates in Relevant Blood Cultures Frequency (n)
P. aeruginosa 10
S. epidermidis 7
S. hominis 7
E. faecalis 5
E. coli 4
Candida albicans 4
Enterobacter cloacae 3
Klebsiella pneumoniae 3
S. aureus (including MRSA) 3
S. haemolyticus 3
E. faecium 2
K. oxytoca 2
Acinetobacter baumanii 1
A. jejunii 1
A. lwoffi 1
C. krusei 1
C. parapsilosis 1
Chryseobacterium indologenes 1
Corynebacterium spp. 1
E. asburiae 1
Leclercia adecarboxylata 1
Proteus mirabilis 1
Proteus monteilii 1
Serratia marcescens 1
Streptococcus dysgalactiae 1
4. Discussion, Literature Review
This study represents a large series of S. maltophilia bacteraemia in Hungary, accounting for a broad
patient population, reported from a general tertiary care hospital, together with the resistance levels of
the isolates for SMX/TMP, in addition to a range of antibiotics for SMX/TMP resistant strains. Although
the resistance level of S. maltophilia is well-characterized in the literature from respiratory infections
and cystic fibrosis patients, there is a relatively small amount of studies regarding S. maltophilia
bacteremia and associated resistance levels. The following section is dedicated to the review of the
relevant literature concerning this topic (summarized in Table 2).
In the study of Ebara et al., the retrospective epidemiological characterization of two medical
hospitals were performed: the corresponding susceptibility rates of these isolates were 87.5% for
SMX/TMP and 75.5% for levofloxacin [46]. In a retrospective, single-center study in Japan, spanning
eight years, Hotta el al. identified 54 cases of clinically relevant S. maltophilia bacteremia, with SMX/TMP
resistance levels around 18.0% and 100.0% minocycline susceptibility [47]. In addition, this study
found that S. maltophilia bacteremia was associated with a significantly higher mortality rate (p =
0.012), compared to other non-fermenting Gram-negative pathogens. In a similar study, Sumida et al.
reported 30 cases of S. maltophilia bloodstream infections and also found a significantly higher mortality
rate (p = 0.047; in this study, resistance rates were not reported) compared to other non-fermenting
Gram-negative bacteria [48]. During a 13-year-long retrospective, single-center survey in Japan,
Araoka et al. found that the overall mortality rate associated with S. maltophilia bacteremia was as
high as 51.0% [49]. In a single-center study, aiming pediatric patients, Wu et al. reported SMX/TMP
resistance levels of 9.0% during a 10-year period, with a crude mortality rate of 40.6% [50]. Caylan et al.
published the results of a 4-year-long survey of a Turkish hospital, in which the susceptibility of 190 S.
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maltophilia strains (67.9% had a nosocomial origin; 36.5% presented as bacteremia) was evaluated [51].
Ninety-four percent of strains were susceptible to SMX/TMP, while this number was significantly lower
for ticarcillin/clavulanate and ciprofloxacin (79.0% and 53.5%, respectively). In another study from
Turkey, Gozel et al. reported the epidemiological results of S. maltophilia infections in a 7-year period:
49.3% of infections were primary bacteremia and resistance rates were 17.1% for SMX/TMP and 2.9%
for levofloxacin [52]. Ubeda et al. studied the prevalence and antibiotic resistance levels of a Spanish
university hospital in a 7-year period. In this study, 78.0% of S. maltophilia cases were of nosocomial
origin, and one-third of these cases were polymicrobial bacteremia. Ninety percent of isolates were
susceptible to SMX/TMP, while ticarcillin/clavulanate susceptibility was 77.0% and ciprofloxacin
susceptibility was 60.0% [53]. In a study of the same length, Garazi et al. reported 102 patients with
S. maltophilia bacteremia in two tertiary care centers in New York [54]. This paper highlighted the
importance of careful evaluation of CVCs, as most of the patents had a central venous access device
(94.1%). Nosocomial acquisition was the predominant form (77.5%) and resistance levels to SMX/TMP,
levofloxacin and ticarcillin/clavulanic acid were 2.9%, 7.1% and 50.8%, respectively. Muder et al.
evaluated S. maltophilia bacteremia in multiple hospitals in Pittsburg and found 91 episodes; the 14-day
mortality of the patients was 21.0%, while SMX/TMP susceptibility was 94.0% [55]. In a Canadian study,
Church et al. screened invasive S. maltophilia isolates: out of 90 patients, 69.0% had a bloodstream
infection, and 17.0% of the isolates were resistant to SMX/TMP. The same study also tested the efficacy
of antibiotic combinations in vitro, and found that SMX/TMP + colistin and SMX/TMP + minocycline
were the most effective [56]. Friedmann et al. performed a retrospective characterization of bloodstream
infections in a tertiary-care hospital in Melbourne, Australia: 80.0% of cases were of nosocomial origin
and the susceptibility rates of the strains were SMX/TMP 80%, chloramphenicol 75.5% and ceftazidime
64.5% [57]. In a retrospective, single-center study from Korea, Cho et al. recorded S. maltophilia
bloodstream infections: 31 cases were identified, with susceptibility levels of 88.9%, 40.7% and 44.0%
for SMX/TMP, ticarcillin/clavulanic acid and levofloxacin, respectively [58]. A Greek 6-year-long,
single-center study by Samonis et al. evaluated the susceptibility of invasive S. maltophilia isolates:
infection-related mortality was 14.7%, while resistance levels were 14.7%, 8.8%, 14,7% and 17.6% for
SMX/TMP, colistin, netilmicin and ciprofloxacin, respectively [59]. Wu et al. reported the results of
the Taiwan Surveillance of Antimicrobial Resistance (TSAR; 1998–2008), which enrolled 38 hospitals,
concluding that SMX/TMP (17.5% resistance) and minocycline (96.0% susceptibility) remained the two
antimicrobials with the best in vitro activities against S. maltophilia [60]. Meyer et al. reported the results
of the SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care
Units) prospective unit- and laboratory-based surveillance system in Germany [61]. The study found
that the resistance levels in S. maltophilia strains isolated from German ICU patients were the following:
SMX/TMP 10.3%, ciprofloxacin: 35.8% and piperacillin/tazobactam 60.7%. Compared to our results in
the Southern Great Plain of Hungary, Juhász et al. found somewhat differing susceptibility patterns in
a 3-year-long, single-center survey in the Central Region of Hungary: the in vitro susceptibilities were
99.0% for SMX/TMP, 75.0% for levofloxacin, 12.0% for tigecycline and 9.0% for colistin [44]. The same
study group characterized the susceptibilities of SMX/TMP-resistant isolates and the efficacy of drug
combinations in the same region. They found that 83.3% of isolates carried the sul1 gene and none of
these strains were susceptible to colistin or tigecycline, while levofloxacin/moxifloxacin was effective
in only 37% of cases. At the same time, the most effective combination in vitro was moxifloxacin and
ceftazidime [34,62].
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Table 2. Summary of the literature regarding susceptibility trends of S. maltophilia [34,46–62].
Ratio of Susceptible Isolates
First Author Study Years Country SMX/TMP CIP or LEV TIC/CLAV CEFTZ MINO COL Other
Friedmann et al. 1988–1997 Australia 80.0% - - 64.5% - - Chloraphenicol: 75.5%
Ubeda et al. 1990–1996 Spain 90.0% 60.0% 77.0% 62.0% - - -
Muder et al. 1991–1994 USA (Pittsburg) 94.0% - - - - - -
Wu et al. 1993–2003 China 91.0% - - - - - -
Wu et al. 1998–2008 China 82.5% - - 96.0% - -
Church et al. 1999–2009 Canada 83.0% - - - - - -
Caylan et al. 2000–2003 Turkey 94.0% 79.0% 53.5% - - - -
Garazi et al. 2001–2007 USA (New York) 97.1% 92.9% 49.2% 53.0% - - -
Meyer et al. 2003–2004 Germany 89.7% 64.2% - - - - Piperacillin/tazobactam: 29.3%
Samonis et al. 2005–2010 Greece 85.3% 82.4% - - - 91.2% Netilmicin: 85.3%
Hotta et al. 2005–2013 Japan 82.0% - - - 100.0% - -
Gokhan et al. 2006–2013 Turkey 82.9% 97.1% - - - -
Ebara et al. 2007–2013 Japan 87.5% 75.5% - - - - -
Juhász et al. 2009–2011 Hungary 99.9% 75.0% - - 9.0% Tigecycline: 12.0%
Cho et al. 2009–2014 Rep. of Korea 88.9% 44.0% 40.0% - - - -
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In several cases (both in the literature findings, and in our own experience), S. maltophilia
was isolated with another significant pathogen. This may bring additional therapeutic
challenges, especially if the mentioned co-pathogen is also resistant to several antibiotics (e.g.,
carbapenem-resistant Pseudomonas and Acinetobacter, extended-spectrum β-lactamase-producing
Enterobacteriaceae, methicillin-resistant S. aureus [MRSA]) [63–65]. Although evidence of the benefits of
combination therapy is limited and its precise role in clinical practice is uncertain, there is an increasing
amount of literature regarding its efficacy (especially in cases of SMX/TMP-resistance). Combinations
usually include 2–3 agents, in the following setup: SMX/TMP or fluoroquinolones plus ceftazidime
or ticarcillin/clavulanate plus minocycline/tigecycline and/or aminoglycosides and/or colistin and/or
rifampin and/or chloramphenicol [7,31]. If in vitro susceptibility to these drugs is observed, a synergy
assay (using the E-test synergy method or the checkerboard microplate method) is recommended before
the administration of these drugs to the patients [66,67]. The intravenous dosing of colistin (the desirable
plasma concentration is around 2 mg/L) is difficult due to the pharmacokonetic/pharmacodynamic
properties of the drug, its nephrotoxicity and the interpatient variability. The latter is especially
challenging in patients with renal failure and severe underlying conditions [68]. Therefore, the use
of inhalational/aerosolized colistin (especially if the source of the bacteremia is the lungs) is gaining
increasing attention [69,70].
5. Conclusions
S. maltophilia bloodstream infections are thought to be infrequent, however, their relevance is
increasing in the era of invasive surgical interventions and heavily immunosuppressed patients, due
to cancer chemotherapy and transplantation. These infections are associated with high morbidity
and mortality, especially in the abovementioned, vulnerable patient groups. There is no clear answer
whether S. maltophilia bacteremia is a cause of death or a marker of poor prognosis in these patients
(i.e., advanced malignancies, prolonged mechanical ventilation and/or ICU stay, and long courses of
broad-spectrum antibiotics), and this remains a controversial topic. The aim of the present study was
to highlight some of the features of these infections locally and compare our findings with international
trends. In line with the literature, S. maltophilia bacteremia mainly affected post-operative patients,
patients with severe injuries or underlying conditions (malignant hematologic diseases and solid
tumors) and patients over 60 years of age. The ratio of SMX/TMP-resistant strains was similar to the
global average (5–20%), but somewhat higher than the reports of other European countries. Some
limitations of this study must be acknowledged. Firstly, due to the inability to access the medical
records of the individual patients affected, the presence and nature of symptoms of the patients were
unknown. For the same reason, the correlation between the presence/absence of all relevant risk factors
and S. maltophilia bacteremia could not be assessed. There is a risk of selection/referral bias, as studies
describing the prevalence of infectious diseases and resistance trends are mainly tertiary-care centers,
which generally correspond to patients with more severe conditions or underlying illnesses, compared
to community-based settings [71].
Due to the selection pressure of the more pronounced use of carbapenem antibiotics, the
laboratories should expect a more frequent occurrence of SMX/TMP-resistant strains. Treatment of
confirmed S. maltophilia infections should be started as soon as possible, as delays in the selection
of appropriate therapy may contribute to an increase in mortality. The increasing prevalence of
SMX/TMP-resistant isolates is a serious concern for clinicians. Institutions must establish therapeutic
protocols for these cases, based on local resistance trends and international guidelines. In addition,
the relevance of various combination therapies needs to be further evaluated in a controlled, clinical
setting. The appropriate sampling technique and consultation between treating physicians and clinical
microbiologists is essential for the adequate treatment of these patients.
Diseases 2019, 7, 41 9 of 13
Author Contributions: M.G. conceived and designed the study. E.U. identified the bacterial isolates and
interpreted susceptibility testing results. M.G. and E.U. performed data collection and analysis, wrote and revised
the full paper.
Funding: This research received no external funding. Part of the APC was funded by MDPI.
Acknowledgments: The authors would like to thank Tünde Deák and Erika Karasz for the excellent laboratory
assistance during the routine diagnostic work. M.G. was supported by the National Youth Excellence Scholarship
[Grant Number NTP-NTFÖ-18-C-0225] and the ESCMID Mentorship and Observership Programme.
Conflicts of Interest: The authors declare no conflict of interest, monetary or otherwise.
Abbreviations
AST antimicrobial susceptibility testing
ASCC Albert Szent-Györgyi Clinical Center
CLSI Clinical and Laboratory Standards Institute
CF cystic fibrosis
CoNS coagulase-negative Staphylococcus
COL colistin
CVC central venous catheter
EUCAST European Committee for Antimicrobial Susceptibility Testing
HAP hospital-acquired pneumonia
HIV human immunodeficiency virus
ID identification
ICU intensive care unit
LEV levofloxacin
LPS lipopolysaccharide
MALDI-TOF
MS
matrix-assisted laser desorption-ionization time-of-flight mass spectrometry
MDR multidrug-resistant
NSS non species-specific breakpoints
SMX/TMP sulfamethoxazole-trimetoprim
TGC tigecycline
TPN total parenteral nutrition
TTP time-to-positivity
VAP ventilator-associated pneumonia
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